Next 10 |
janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...
Merger activity increased last week with six new deals announced. $50 billion worth of deals announced in a single week. Thermo Fisher Scientific to acquire PPD Inc. For further details see: Merger Arbitrage Mondays - Microsoft's Acquisition Of Nuance Offers A 5% Spread ...
Amgen (AMGN) announces that it has completed its previously announced tender offer to purchase all outstanding shares of Five Prime Therapeutics (FPRX) in a deal valued at ~$1.9B."Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 trial-re...
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics PR Newswire THOUSAND OAKS, Calif. , April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all out...
Amgen (NASDAQ: AMGN) recently announced plans to acquire Five Prime Therapeutics (NASDAQ: FPRX) for approximately $1.9 billion. The deal gives Amgen rights to bemarituzumab, which has made it through phase 2 testing. In this video from Motley Fool Live , recorded on ...
FPRX saw strong results from bemarituzumab. However, there were a couple concerns, and approval is probably a couple years away. Given that, the Amgen deal seems to be a good one. For further details see: Five Prime Is Acquired By Amgen In A Shareholder-Friendly Deal
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The cancellation is the result of the co...
On Thursday, Amgen (NASDAQ: AMGN) became the latest big drugmaker to announce an acquisition in 2021. The biotech giant told investors that it will acquire Five Prime Therapeutics (NASDAQ: FPRX) for $1.9 billion in cash. Five Prime Therapeutics is a clinical-stage biotec...
Shares of Five Prime Therapeutics (NASDAQ: FPRX) were skyrocketing 78% higher as of 11:22 a.m. EST on Thursday. The huge jump came after Amgen (NASDAQ: AMGN) announced plans to acquire Five Prime for close to $1.9 billion. Some investors might have sensed that something ...
Gainers: Five Prime Therapeutics (FPRX) +78%, Ampio Pharmaceuticals (AMPE) +10%, Soligenix (SNGX) +7%.Losers: BioVie (BIVI) -29%, Schrodinger (SDGR) -25%, KemPharm (KMPH) -19%, Anchiano Therapeutics (ANCN) -15%, AbCellera Biologics (...
News, Short Squeeze, Breakout and More Instantly...
Five Prime Therapeutics Inc. Company Name:
FPRX Stock Symbol:
NASDAQ Market:
Five Prime Therapeutics Inc. Website:
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics PR Newswire THOUSAND OAKS, Calif. , April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all out...
Amgen (NASDAQ: AMGN) recently announced plans to acquire Five Prime Therapeutics (NASDAQ: FPRX) for approximately $1.9 billion. The deal gives Amgen rights to bemarituzumab, which has made it through phase 2 testing. In this video from Motley Fool Live , recorded on ...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The cancellation is the result of the co...